Kathy Wang

Kathy Wang is an accomplished regulatory affairs professional with extensive experience in the medical devices and combination products sectors. Currently serving as Director of Devices and Digital Therapeutics at AstraZeneca since May 2019, Kathy leads device aspects of combination product development and oversees regulatory strategies and health authority interactions. Prior roles include Associate Director at AstraZeneca, Principal Regulatory Affairs Specialist at Cochlear Acoustics, and Senior Regulatory Affairs Associate at Cochlear Limited, where Kathy developed global regulatory strategies and facilitated submissions to regulatory bodies. Kathy's career began at Pfizer Consumer Healthcare and Allergan Australia, focusing on regulatory affairs and quality assurance. Kathy holds a Master's degree in Medical Science from UNSW.